BlackRock Amends Kymera Therapeutics Stake, Remains Passive Investor
Ticker: KYMR · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**BlackRock still owns a chunk of Kymera, but they're just holding, not trying to run the show.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of Kymera Therapeutics, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous statement, shows BlackRock's continued significant, but passive, investment in Kymera. For investors, this means a major institutional player like BlackRock still sees value in Kymera, which can be a positive signal, but their passive stance suggests they aren't looking to influence company management.
Why It Matters
This filing confirms BlackRock's ongoing substantial, yet passive, ownership in Kymera Therapeutics, signaling institutional confidence without any intent to control the company.
Risk Assessment
Risk Level: low — This filing is routine and indicates a stable, passive institutional investment, posing minimal risk to current or prospective shareholders.
Analyst Insight
An investor should note BlackRock's continued passive stake as a sign of institutional confidence, but understand that this filing doesn't suggest any upcoming strategic changes or activist involvement from BlackRock.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Kymera Therapeutics, Inc. (company) — the subject company whose securities are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A amendment
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It indicates that a passive institutional investor, in this case, BlackRock Inc., owns a significant stake (over 5%) in a company, Kymera Therapeutics, Inc., but does not intend to influence or control the company's management or policies.
Who is the reporting person in this filing?
The reporting person is BlackRock Inc., a major asset management firm with a Central Index Key (CIK) of 0001364742.
What is the subject company whose shares are being reported?
The subject company is Kymera Therapeutics, Inc., a biological products company with a CIK of 0001815442.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated in the filing.
What rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Kymera Therapeutics, Inc. (KYMR).